South Korea has approved 15 potential COVID-19 treatments and vaccines for clinical testing as it steps up efforts to combat the pandemic, reported The Korea Herald.
The Ministry of Food and Drug Safety said most of the candidates being tested are from foreign companies, but two have been made by local drugmakers, including Bukwang Pharmaceutical and Chong Kun Dang Pharmaceutical.
Bukwang's Levovir was originally developed to treat hepatitis B, while Chong Kun Dang's drug nafabelltan is an anticoagulant that may help patients infected with COVID-19.
Meanwhile, GC Pharma, another South Korean pharmaceutical firm, is preparing to conduct Phase II trials for a potential treatment that uses blood plasma taken from people who have fully recovered from coronavirus infections.
As for vaccine candidates, the ministry said GX-19, a vaccine material made by South Korea's Genexine, is being examined by experts ahead of clinical tests.
To read more NewsPoints articles, click here.